Hemostemix Inc. (CVE:HEM – Get Free Report)’s share price traded up 46.7% during trading on Saturday . The company traded as high as C$0.11 and last traded at C$0.11. 1,473,342 shares traded hands during trading, an increase of 283% from the average session volume of 384,669 shares. The stock had previously closed at C$0.08.
Hemostemix Stock Performance
The company has a quick ratio of 0.48, a current ratio of 0.04 and a debt-to-equity ratio of -55.07. The business has a fifty day simple moving average of C$0.11 and a 200-day simple moving average of C$0.12. The firm has a market cap of C$19.58 million, a P/E ratio of -2.97 and a beta of 1.39.
Hemostemix Company Profile
Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia.
Recommended Stories
- Five stocks we like better than Hemostemix
- Where to Find Earnings Call Transcripts
- Auto Tariffs Are Coming Down: 3 Stocks to Benefit Soon
- With Risk Tolerance, One Size Does Not Fit All
- Tencent Music Stock Outshines Spotify as China’s Music Giant
- The Risks of Owning Bonds
- DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?
Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.com's FREE daily email newsletter.
